Table 2

Predictors associated with dabigatran use, results from the logistic regression analysis

OR95% CIp Value
Male1.00
Female0.70(0.64 to 0.76)<0.001
Age 65–741.14(0.96 to 1.36)0.14
Age ≥751.50(1.24 to 1.82)<0.001
Heart failure1.23(1.05 to 1.44)0.01
Hypertension1.39(1.13 to 1.71)0.002
Diabetes1.16(1.01 to 1.32)0.03
Previous thromboembolism1.18(0.97 to 1.44)0.11
Vascular disease1.02(0.91 to 1.16)0.14
Previous bleeding1.10(0.94 to 1.30)0.24
CHADS2 group*0.81(0.70 to 0.93)0.003
CHA2DS2–VASc group†1.00(0.88 to 1.14)0.98
HAS-BLED group‡1.03(0.89 to 1.19)0.73
  • *CHADS2: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischaemic attack.

  • †CHA2DS2–VASc: CHADS2, adding vascular disease, age 65–75 and female sex.

  • ‡HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio (left out due to lack of information, as carried out previously), elderly (>65 years), drugs/alcohol concomitantly.